A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation
- PMID: 28496713
- PMCID: PMC3521534
- DOI: 10.4022/jafib.415
A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation
Abstract
Cardiac hypertrophy is a major risk factor for the development of atrial fibrillation (AF). However, there are few animal models of AF associated with cardiac hypertrophy. In this study, we describe the in vivo electrophysiological characteristics and histopathology of a mouse model of cardiac hypertrophy that develops AF. Myostatin is a well-known negative regulator of skeletal muscle growth that was recently found to additionally regulate cardiac muscle growth. Using cardiac-specific expression of the inhibitory myostatin pro-peptide, we generated transgenic (TG) mice with dominant-negative regulation of MSTN (DN-MSTN). One line (DN-MSTN TG13) displayed ventricular hypertrophy, as well as spontaneous AF on the surface electrocardiogram (ECG), and was further evaluated. DN-MSTN TG13 had normal systolic function, but displayed atrial enlargement on cardiac MRI, as well as atrial fibrosis histologically. Baseline ECG revealed an increased P wave duration and QRS interval compared with wild-type littermate (WT) mice. Seven of 19 DN-MSTN TG13 mice had spontaneous or inducible AF, while none of the WT mice had atrial arrhythmias (p<0.05). Connexin40 (Cx40) was decreased in DN-MSTN TG13 mice, even in the absence of AF or significant atrial fibrosis, raising the possibility that MSTN signaling may play a role in Cx40 down-regulation and the development of AF in this mouse model. In conclusion, DN-MSTN TG13 mice represent a novel model of AF, in which molecular changes including an initial loss of Cx40 are noted prior to fibrosis and the development of atrial arrhythmias.
Figures
References
-
- Go A S, Hylek E M, Phillips K A, Chang Y, Henault L E, Selby J V, Singer D E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 09;285 (18):2370–5. - PubMed
-
- Vaziri S M, Larson M G, Benjamin E J, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994 Feb;89 (2):724–30. - PubMed
-
- Robinson K, Frenneaux M P, Stockins B, Karatasakis G, Poloniecki J D, McKenna W J. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. 1990 May;15 (6):1279–85. - PubMed
-
- Okin Peter M, Wachtell Kristian, Devereux Richard B, Harris Katherine E, Jern Sverker, Kjeldsen Sverre E, Julius Stevo, Lindholm Lars H, Nieminen Markku S, Edelman Jonathan M, Hille Darcy A, Dahlöf Björn. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006 Sep 13;296 (10):1242–8. - PubMed
-
- Saba Samir, Janczewski Andrzej M, Baker Linda C, Shusterman Vladimir, Gursoy Erdal C, Feldman Arthur M, Salama Guy, McTiernan Charles F, London Barry. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am. J. Physiol. Heart Circ. Physiol. 2005 Oct;289 (4):H1456–67. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous